

SKYWAY XPRO 1/14

Version 7 / IRL Revision Date: 22.03.2023 102000014326 Print Date: 22.03.2023

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name SKYWAY XPRO

UFI Y9G0-80MQ-5003-KNSV

Product code (UVP) 79053649, 86197928

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use Fungicide

1.3 Details of the supplier of the safety data sheet

Supplier Bayer CropScience Ltd

Bayer Ltd

1st Floor, The Grange Offices The Grange, Brewery Road

Stillorgan

A94 H2K7 Co. Dublin

Ireland

Telephone +353 1 216 3300

Responsible Department Email: gb-bcs-crop-regulatory-affairs@bayer.com

1.4 Emergency telephone no.

Emergency telephone no. 00800 1020 3333 (24 hr) (not available on non-contract mobile phones)

For Medical Professionals: You can also contact Dublin NPIS.

For Members of the Public: You can also contact 01 809 2166 (for Republic of Ireland).

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Classification in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Acute toxicity: Category 4

H302 Harmful if swallowed.

Skin sensitisation: Category 1

H317 May cause an allergic skin reaction.

Specific target organ toxicity - single exposure: Category 3

H335 May cause respiratory irritation.

Reproductive toxicity: Category 2

H361d Suspected of damaging the unborn child.



SKYWAY XPRO 2/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Acute aquatic toxicity: Category 1

H400 Very toxic to aquatic life.

Chronic aquatic toxicity: Category 1

H410 Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Hazard label for supply/use required.

Hazardous components which must be listed on the label:

- Bixafen
- Prothioconazole
- Tebuconazole
- N,N-Dimethyl decanamide







Signal word: Warning Hazard statements

H302 Harmful if swallowed.

H317 May cause an allergic skin reaction.
H335 May cause respiratory irritation.

H361d Suspected of damaging the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

EUH401 To avoid risks to human health and the environment, comply with the instructions for

use.

Precautionary statements

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor/ physician.

P410 Protect from sunlight.

P501 Dispose of contents/container to a licensed hazardous waste disposal contractor or

collection site, except for triple rinsed empty containers which can be disposed of as

non-hazardous waste.

2.3 Other hazards

No additional hazards known beside those mentioned.

Tebuconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Prothioconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). Bixafen: This

substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB). 2-Ethylhexanol propylene ethyleneglycol ether: Not applicable N,N-Dimethyldecanamide: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

Ecological information:

The substance/mixture does not contain components considered to



SKYWAY XPRO

3/14 Version 7 / IRL Revision Date: 22.03.2023 102000014326 Print Date: 22.03.2023

> have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to

have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures

Chemical nature

Emulsifiable concentrate (EC) Bixafen 75 g/l, Prothioconazole 100 g/l, Tebuconazole 100 g/l

Hazardous components

Hazard statements according to Regulation (EC) No. 1272/2008

Name	CAS-No. /	Classification	Conc. [%]
	EC-No. / REACH Reg. No.	REGULATION (EC) No 1272/2008	
Bixafen	581809-46-3	Aquatic Acute 1, H400 Aquatic Chronic 1, H410	7.4
Prothioconazole	178928-70-6	Aquatic Acute 1, H400 Aquatic Chronic 1, H410	9.9
Tebuconazole	107534-96-3 403-640-2	Acute Tox. 4, H302 Repr. 2, H361d Aquatic Acute 1, H400 Aquatic Chronic 1, H410	9.9
2-Ethylhexanol propylene ethyleneglycol ether	64366-70-7	Aquatic Chronic 3, H412	> 1 – < 25
N,N-Dimethyl decanamide	14433-76-2 238-405-1 01-2119485027-36-XXXX	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Aquatic Chronic 3, H412	> 25

Further information

Bixafen	581809-46-3	M-Factor: 10 (acute)
Prothioconazole	178928-70-6	M-Factor: 10 (acute), 1 (chronic)
Tebuconazole	107534-96-3	M-Factor: 1 (acute), 10 (chronic)

For the full text of the H-Statements mentioned in this Section, see Section 16.

Particle characteristics

This substance/ mixture does not contain nanoforms



SKYWAY XPRO 4/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice Move out of dangerous area. Place and transport victim in stable

position (lying sideways). Remove contaminated clothing immediately

and dispose of safely.

Inhalation Move to fresh air. Keep patient warm and at rest. Call a physician or

poison control center immediately.

Skin contact Wash off thoroughly with plenty of soap and water, if available with

polyethyleneglycol 400, subsequently rinse with water. If symptoms

persist, call a physician.

Eye contact Rinse immediately with plenty of water, also under the eyelids, for at

least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation

develops and persists.

Ingestion Rinse mouth. Do NOT induce vomiting. Call a physician or poison

control center immediately.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms No symptoms known or expected.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment Treat symptomatically. In case of ingestion gastric lavage should be

considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium

sulphate is always advisable. There is no specific antidote.

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable Use water spray, alcohol-resistant foam, dry chemical or carbon

dioxide.

Unsuitable High volume water jet

5.2 Special hazards arising from the substance or

mixture

In the event of fire the following may be released:, Hydrogen chloride (HCI), Hydrogen cyanide (hydrocyanic acid), Hydrogen fluoride, Carbon monoxide (CO), Sulphur oxides, Nitrogen oxides (NOx)

5.3 Advice for firefighters

Special protective equipment for firefighters

In the event of fire and/or explosion do not breathe fumes. In the event

 uipment for firefighters
 of fire, wear self-contained breathing apparatus.

Further information Contain the spread of the fire-fighting media. Do not allow run-off from

fire fighting to enter drains or water courses.



SKYWAY XPRO 5/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Precautions Avoid contact with spilled product or contaminated surfaces. Use

personal protective equipment.

6.2 Environmental

precautions

Do not allow to get into surface water, drains and ground water. If the product contaminates rivers and lakes or drains inform respective

authorities.

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid

binder, universal binder, sawdust). Clean contaminated floors and objects thoroughly, observing environmental regulations. Keep in

suitable, closed containers for disposal.

6.4 Reference to other

sections

Information regarding safe handling, see section 7.

Information regarding personal protective equipment, see section 8.

Information regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Advice on safe handling
No specific precautions required when handling unopened

packs/containers; follow relevant manual handling advice. Ensure

adequate ventilation.

Advice on protection against fire and explosion

Keep away from heat and sources of ignition.

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes

separately. Wash hands before breaks and immediately after handling the product. Wash hands immediately after work, if necessary take a shower. Remove soiled clothing immediately and clean thoroughly before using again. Garments that cannot be cleaned must be

destroyed (burnt).

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage

areas and containers

Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated place. Store in a place accessible by authorized

persons only. Protect from freezing. Keep away from direct sunlight.

Suitable materials Coextruded containers with an internal barrier layer made of ethylene

vinyl alcohol copolymer (EVOH)

7.3 Specific end use(s) Refer to the label and/or leaflet.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis



SKYWAY XPRO 6/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Tebuconazole	107534-96-3	0.2 mg/m3 (SK-ABS)	OES BCS*
Prothioconazole	178928-70-6	1.4 mg/m3 (SK-ABS)	OES BCS*
Bixafen	581809-46-3	0.6 mg/m3 (TWA)	OES BCS*

^{*}OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

8.2 Exposure controls

Personal protective equipment

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

Respiratory protection

Wear respirator with an organic vapours and gas filter mask (protection factor 10) conforming to EN140 type A or equivalent. Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's instructions regarding wearing and maintenance.

Hand protection

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating, drinking, smoking or using the toilet.

Material Nitrile rubber
Rate of permeability > 480 min
Glove thickness > 0.4 mm
Protective index Class 6

Directive Protective gloves complying with EN

374.

Eye protection

Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Skin and body protection

Wear standard coveralls and Category 3 Type 4 suit.

If there is a risk of significant exposure, consider a higher protective

type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and

should be professionally laundered frequently.

If chemical protection suit is splashed, sprayed or significantly contaminated, decontaminate as far as possible, then carefully

remove and dispose of as advised by manufacturer.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Form Liquid, clear to slightly turbid



7/14

SKYWAY XPRO

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Colour yellow to brown

Odour aromatic

Odour Threshold

Melting point/range

Boiling Point

Flammability

Upper explosion limit

No data available

Flash point > 103 °C

Auto-ignition temperature No data available

Ignition temperature 370 °C

Self-accelarating decomposition temperature

(SADT)

No data available

pH 4.5 - 6.5 (1 %) (23 °C) (deionized water)

Viscosity, dynamic No data available

Viscosity, kinematic 101 mm²/s (20 °C) Shear rate of 100/sec

Water solubility miscible

Partition coefficient: n-

octanol/water

Tebuconazole: log Pow: 3.7

Prothioconazole: log Pow: 3.82 (20 °C) (pH 7)

Bixafen: log Pow: 3.3 (40 °C)

2-Ethylhexanol propylene ethyleneglycol ether:

No data available

N,N-Dimethyldecanamide: log Pow: 2.46

Surface tension 27 mN/m (25 °C)

Determined in the undiluted form.

Vapour pressure No data available

Density ca. 1.01 g/cm³ (20 °C)

Relative density

No data available

Relative vapour density

No data available

Assessment nano particles This substance/ mixture does not contain nanoforms

Particle size No data available

9.2 Other information



SKYWAY XPRO 8/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Explosivity Not explosive

Oxidizing properties No oxidizing properties

Evaporation rate No data available

Other physico-chemical

properties

Further safety related physical-chemical data are not known.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity Stable under normal conditions.

10.2 Chemical stability Stable under recommended storage conditions.

10.3 Possibility of No hazardous reactions when stored and handled according to

hazardous reactions prescribed instructions.

10.4 Conditions to avoid Extremes of temperature and direct sunlight.

10.5 Incompatible materials Store only in the original container.

10.6 Hazardous

decomposition products

No decomposition products expected under normal conditions of use.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on hazard classes as defined in regulation (EC) No 1272/2008

Acute oral toxicity LD50 (Rat) 550 - 2,000 mg/kg

Acute inhalation toxicity

During intended and foreseen applications, no respirable aerosol is

formed.

Irritating to respiratory system.

The value mentioned relates to N,N-dimethylacetamide.

Acute dermal toxicity LD50 (Rat) > 2,000 mg/kg

No deaths

Skin corrosion/irritationNo skin irritation (Rabbit)Serious eye damage/eyeNo eye irritation (Rabbit)

irritation

Respiratory or skin Skin: Sensitising (Mouse)

sensitisation OECD Test Guideline 429, local lymph node assay (LLNA)

Assessment STOT Specific target organ toxicity – single exposure

Tebuconazole: Based on available data, the classification criteria are not met.



9/14

SKYWAY XPRO

Version 7 / IRL Revision Date: 22.03.2023 102000014326 Print Date: 22.03.2023

Prothioconazole: Based on available data, the classification criteria are not met.

Bixafen: Based on available data, the classification criteria are not met.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecan-1-amide: May cause respiratory irritation.

Assessment STOT Specific target organ toxicity - repeated exposure

Tebuconazole did not cause specific target organ toxicity in experimental animal studies.

Prothioconazole did not cause specific target organ toxicity in experimental animal studies.

Bixafen did not cause human relevant specific target organ toxicity in experimental animal studies.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide did not cause specific target organ toxicity in experimental animal studies.

Assessment mutagenicity

Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Prothioconazole was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Bixafen was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

2-Ethylhexanol propylene ethyleneglycol ether is not considered mutagenic.

N,N-Dimethyldecanamide was not genotoxic in a battery of in vitro tests.

Assessment carcinogenicity

Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following organ(s): Liver. The mechanism of tumour formation is not considered to be relevant to man.

Prothioconazole was not carcinogenic in lifetime feeding studies in rats and mice.

Bixafen was not carcinogenic in lifetime feeding studies in rats and mice.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide is not considered carcinogenic.

Assessment toxicity to reproduction

Tebuconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Tebuconazole is related to parental toxicity.

Prothioconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Prothioconazole is related to parental toxicity.

Bixafen did not cause reproductive toxicity in a two-generation study in rats.

2-Ethylhexanol propylene ethyleneglycol ether: Based on available data, the classification criteria are not met.

N,N-Dimethyldecanamide is not considered a reproductive toxicant at non-maternally toxic dose levels.

Assessment developmental toxicity

Tebuconazole caused developmental toxicity only at dose levels toxic to the dams. Tebuconazole caused an increased incidence of post implantation losses, an increased incidence of non-specific malformations.

Prothioconazole caused developmental toxicity only at dose levels toxic to the dams. The developmental effects seen with Prothioconazole are related to maternal toxicity.

Bixafen did not cause developmental toxicity in rats and rabbits.

2-Ethylhexanol propylene ethyleneglycol ether: This information is not available.

N,N-Dimethyldecanamide did not cause developmental toxicity in rats and rabbits.

Aspiration hazard



SKYWAY XPRO 10/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Based on available data, the classification criteria are not met.

Further information

No further toxicological information is available.

11.2 Information on other hazards

Endocrine disrupting properties

Assessment The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)) 1.55 mg/l

Exposure time: 96 h

Toxicity to aquatic

invertebrates

EC50 (Daphnia magna (Water flea)) 5.5 mg/l

Exposure time: 48 h

Chronic toxicity to aquatic

invertebrates

NOEC (Daphnia (water flea)): 0.01 mg/l

Exposure time: 21 d

The value mentioned relates to the active ingredient tebuconazole.

Toxicity to aquatic plants IC50 (Raphidocelis subcapitata (freshwater green alga)) 1.93 mg/l

Growth rate; Exposure time: 72 h

ErC50 (Skeletonema costatum) 0.03278 mg/l

Exposure time: 72 h

The value mentioned relates to the active ingredient prothioconazole.

EC10 (Skeletonema costatum) 0.01427 mg/l

Growth rate; Exposure time: 72 h

The value mentioned relates to the active ingredient prothioconazole.

(Lemna gibba (gibbous duckweed)) 0.237 mg/l

Growth rate; Exposure time: 7 d

The value mentioned relates to the active ingredient tebuconazole.

12.2 Persistence and degradability

Biodegradability Tebuconazole:

Not rapidly biodegradable

Prothioconazole:

Not rapidly biodegradable

Bixafen:

Not rapidly biodegradable

2-Ethylhexanol propylene ethyleneglycol ether:

Not readily biodegradable. N,N-Dimethyldecanamide: rapidly biodegradable



SKYWAY XPRO 11/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Koc Tebuconazole: Koc: 769

Prothioconazole: Koc: 1765

Bixafen: Koc: 3869

2-Ethylhexanol propylene ethyleneglycol ether:No data available

12.3 Bioaccumulative potential

Bioaccumulation Tebuconazole: Bioconcentration factor (BCF) 35 - 59

Does not bioaccumulate.

Prothioconazole: Bioconcentration factor (BCF) 19

Does not bioaccumulate.

Bixafen: Bioconcentration factor (BCF) 695

Does not bioaccumulate.

2-Ethylhexanol propylene ethyleneglycol ether:

No data available

N,N-Dimethyldecanamide: Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil Tebuconazole: Slightly mobile in soils

Prothioconazole: Slightly mobile in soils

Bixafen: Slightly mobile in soils

2-Ethylhexanol propylene ethyleneglycol ether: No data available

N,N-Dimethyldecanamide: Slightly mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment Tebuconazole: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Prothioconazole: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

Bixafen: This substance is not considered to be persistent,

bioaccumulative and toxic (PBT). This substance is not considered to be

very persistent and very bioaccumulative (vPvB).

2-Ethylhexanol propylene ethyleneglycol ether: Not applicable N,N-Dimethyldecanamide: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

12.6 Endocrine disrupting properties

Assessment The substance/mixture does not contain components considered to have

endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission

Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

Additional ecological

information

No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods



SKYWAY XPRO 12/14

Version 7 / IRL Revision Date: 22.03.2023 102000014326 Print Date: 22.03.2023

Product It is best to use all of the product in accordance with label directions. If it

is necessary to dispose of unused product, please follow container label

instructions and applicable local guidelines.

Contaminated packaging Small containers (< 10 l or < 10 kg) should be rinsed thoroughly using

an integrated pressure rinsing device, or, by manually rinsing three

times.

Add washings to sprayer at time of filling.
Dispose of empty and cleaned packaging safely.
Follow advice on product label and/or leaflet.

Waste key for the unused

product

02 01 08* agrochemical waste containing hazardous substances

SECTION 14: TRANSPORT INFORMATION

ADR/RID/ADN

14.1 UN number **3082**

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es)
14.4 Packaging Group
14.5 Environm. Hazardous Mark
Hazard no.
700
Tunnel Code
9
9
-

This classification is in principle not valid for carriage by tank vessel on inland waterways. Please refer to the manufacturer for further information.

IMDG

14.1 UN number **3082**

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es) 9
14.4 Packaging Group III
14.5 Marine pollutant YES

IATA

14.1 UN number **3082**

14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(BIXAFEN SOLUTION)

14.3 Transport hazard class(es)
14.4 Packaging Group
14.5 Environm. Hazardous Mark
YES

14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

14.7 Transport in bulk according to IMO instruments

No transport in bulk according to the IBC Code.



13/14

SKYWAY XPRO

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Republic of Ireland Regulations

This material may be subject to some or all of the following regulations (and any subsequent ammendments). Users must ensure that any uses and restrictions as indicated on the label and/or leaflet are followed.

Supply and Use

European Communities (Prohibition of Certain Active Substances in Plant Protection Products) Regulations 1981 (SI No 320/1981)

European Communities (Authorization, Placing on the Market, Use and Control of Plant Protection Products) Regulations 2003 (SI No 83/2003)

European Communities (Classification, Packaging and Labelling of Plant Protection Products and Biocide Products) Regulations 2001 (SI No 624/2001

2010 Code of Practice for the Safety, Health and Welfare at Work (Chemical Agents) Regulations, 2001 (SI No 619/2001)

Waste Treatment

Landfill Directive

Regulation on Substances That Deplete the Ozone Layer 1994 (EEC/3093/94)

Further information

WHO-classification: II (Moderately hazardous)

15.2 Chemical safety assessment

A chemical safety assessment is not required.

SECTION 16: OTHER INFORMATION

Text of the hazard statements mentioned in Section 3

H302	Harmful if swallowed.
H315	Causes skin irritation.
H319	Causes serious eye irritation.
H361d	Suspected of damaging the unborn child.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.

Abbreviations and acronyms

ADN European Agreement concerning the International Carriage of Dangerous Goods by

Inland Waterways

ADR European Agreement concerning the International Carriage of Dangerous Goods by

Road

ATE Acute toxicity estimate

CAS-Nr. Chemical Abstracts Service number



SKYWAY XPRO 14/14

 Version 7 / IRL
 Revision Date: 22.03.2023

 102000014326
 Print Date: 22.03.2023

Conc. Concentration

EC-No. European community number ECx Effective concentration to x %

EINECS European inventory of existing commercial substances

ELINCS European list of notified chemical substances

ELV Exposure Limit Value
EN European Standard
EU European Union

IATA International Air Transport Association

IBC International Code for the Construction and Equipment of Ships Carrying Dangerous

Chemicals in Bulk (IBC Code)

ICx Inhibition concentration to x %

IMDG International Maritime Dangerous Goods

LCx Lethal concentration to x %

LDx Lethal dose to x %

LOEC/LOEL Lowest observed effect concentration/level

MARPOL: International Convention for the prevention of marine pollution from ships

N.O.S. Not otherwise specified

NOEC/NOEL No observed effect concentration/level

OECD Organization for Economic Co-operation and Development

RID Regulations concerning the International Carriage of Dangerous Goods by Rail

SI Statutory Instrument
TWA Time weighted average

UN United Nations

WHO World health organisation

The above information is intended to give general health and safety guidance on the storage and transport of the product.

It is not intended to apply to the use of the product for which purposes the product label and any appropriate technical usage literature available should be consulted and any relevant licenses, consents or approvals complied with.

The requirements or recommendations of any relevant site or working procedure, system or policy in force or arising from any risk assessment involving the substance or product should take precedence over any of the guidance contained in this safety data sheet where there is a difference in the information given.

The information provided in this safety data sheet is accurate at the date of publication and will be updated as and when appropriate.

No liability will be accepted for any injury, loss or damage resulting from any failure to take account of information or advice contained in this safety data sheet.

Reason for Revision: Safety Data Sheet according to Regulation (EU) No. 2020/878.

Checked and revised for editorial purposes due to adjustments according to the current Annex II of the REACH regulation.

Safety Data Sheet according to Regulation (EU) No. 2015/830. The following sections have been revised: Section 2: Hazards Identification. Section 3: Composition / Information on Ingredients. Section 16: Other Information.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.